REBEL EM is licensed under a
© 2022 REBEL EM. All rights reserved. | Disclaimer | Website by Innov8 Place.
Archive
Author: Anand Swaminathan
REBEL Cast Ep97: The NoPAC Trial – TXA for Epistaxis?
Background: Epistaxis is a common Emergency Department (ED) complaint with over 450,000 visits per year and a lifetime incidence of 60% (Gifford 2008, Pallin 2005). Standard anterior epistaxis treatment consists of holding pressure, use of local vasoconstrictors, topical application of ...
REBEL Core Cast 50.0 – Superficial Venous Thrombosis
Take Home Points SVT >5cm or <3 cm from the SFJ should be treated with anti-coagulation. The rate of concurrent DVT and PE in patients with SVT is 25% and 5%, respectively.
Does D Stand for Decrease Deterioration + Death? – The Jury is Out for Vitamin D in COVID
Update: This article was removed from the Lancet server on February 19th, 2021 (Link) Background: Vitamin D deficiency is common amongst critically ill patients and there has been ample speculation about a possible role for supplementation (with calcifediol) in the ...
REBEL Cast Ep95: Colchicine in COVID (COLCORONA)? Don’t Believe the Hype.
Background: Science by press release. Not the way any of us would choose to operate but, the COVID pandemic has made this a reality. It’s vital that we understand that while pharmaceutical companies have a responsibility to release this information, ...